Skip to main content
Have a personal or library account? Click to login
Effects Of The Direct Renin Inhibitor Aliskiren On Oxidative Stress In Isolated Rat Heart Cover

Effects Of The Direct Renin Inhibitor Aliskiren On Oxidative Stress In Isolated Rat Heart

EABR. Experimental and Applied Biomedical Research
Volume 16 (2015): Issue 3 (September 2015)
By: ,  ,  ,  ,  ,  ,  ,  ,   and    
Open Access
|Oct 2015
References

References

  1. 1. Angeli F, Reboldi G, Mazzotta G, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf. 2012;7(1):76-85.
    Open DOISearch in Google Scholar
  2. 2. Dzau V. The cardiovascular continuum and renin-angiotensinaldosterone system blockade. J Hypertens-Suppl. 2005; 23: S9-17.
    Open DOISearch in Google Scholar
  3. 3. Pagliaro P, Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther. 2005; 19: 77-87.
    Open DOISearch in Google Scholar
  4. 4. Angeli F, Reboldi G, Poltronieri C et al. Efficacy and safety profile of aliskiren: practical implications for clinicians. Curr Drug Saf. 2014; 9(2): 106-17.
    Open DOISearch in Google Scholar
  5. 5. Sen S, Sabırlı S, Ozyiğit T, Uresin Y. Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. TherAdv Chronic Dis. 2013; 4(5): 232-41.
    Open DOISearch in Google Scholar
  6. 6. Yoshitomi Y, Kawanishi K, Yamaguchi A, et al. Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension. Int Heart J. 2013; 54(2): 88-92.
    Open DOISearch in Google Scholar
  7. 7. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs. 2007; 67(12): 1767-92.
    Open DOISearch in Google Scholar
  8. 8. Zaporowska-Stachowiak I, Hoffmann K, Bryl W, Minczykowski A. Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension. Arch Med Sci. 2014; 10(4): 830-6.
    Open DOISearch in Google Scholar
  9. 9. Maibaum J, Feldman DL. Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Pat. 2003; 13: 589–603.
    Open DOISearch in Google Scholar
  10. 10. Fogari R, Zoppi A. New class of agents for treatment of hypertension: focus on direct renin inhibition. Vasc Health Risk Manag. 2010; 6: 869–82.
    Open DOISearch in Google Scholar
  11. 11. Lizakowski S, Tylicki L, Rutkowski B. Direct renin inhibition – a promising strategy for renal protection? Med SciMonit. 2013; 19: 451–7.
    Search in Google Scholar
  12. 12. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007; 370: 221–9.
    Open DOISearch in Google Scholar
  13. 13. McMurray JJV, Pitt B, Latini R et al. Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008; 1: 17.
    Open DOISearch in Google Scholar
  14. 14. Ben-Menachem E, Kyllerman M, Marklund S. Superoxide dismutase and gluthatione peroxidase function in progressive myoclonus epilepsies. Epilepsy Res. 2000; 40: 33-9.
    Open DOISearch in Google Scholar
  15. 15. Naranjan SD, Temsah MR, Netticadan T. Role of oxidative stress in cardiovascular diseases. Journal of hypertension. 2000; 18.6: 655-73.
    Open DOISearch in Google Scholar
  16. 16. Matavelli LC, Siragy HM. Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. J Cardiovasc Pharmacol. 2013; 61(1): 17-22.
    Open DOISearch in Google Scholar
  17. 17. Wen Zhang, Yi Han, GuoliangMeng, et al. Direct Renin Inhibition With Aliskiren Protects Against Myocardial Ischemia/Reperfusion Injury by Activating Nitric Oxide Synthase Signaling in Spontaneously Hypertensive Rats. J Am Heart Assoc. 2014; 3(1): e000606.
    Open DOISearch in Google Scholar
  18. 18. Green, LC, Wagner DA, Glogowski J, Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R. Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids. Anal. Biochem. 1982; 126: 131–8.
    Search in Google Scholar
  19. 19. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal, Biochem. 1979; 95: 351–8.
    Open DOISearch in Google Scholar
  20. 20. Pick E, Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J. Immunol. Methods. 1980; 38: 161–70.
    Search in Google Scholar
  21. 21. Auclair C, Voisin E. Nitroblue tetrazolium reduction. In: Handbook of methods for oxygen radical research, (Ed R.A. Greenvvald). 1985; 123–32. CRC Press, Boca Raton.
    Search in Google Scholar
  22. 22. Frohlich ED. State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension. 1999; 34: 782–9.
    Open DOISearch in Google Scholar
  23. 23. Weng LQ, Zhang WB, Ye Y et al. Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice. Acta Pharmacol Sin. 2014; 35(8): 1005-14.
    Open DOISearch in Google Scholar
  24. 24. Santuzzi CH, Tiradentes RV, Mengal V et al. Combined aliskiren and L-arginine treatment has antihypertensive effects and prevents vascular endothelial dysfunction in a model of renovascular hypertension. Braz J Med Biol Res. 2015; 48(1): 65-76.
    Open DOISearch in Google Scholar
  25. 25. Savvatis K, Westermann D, Schultheiss HP, Tschope C. First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination. Integr Blood Press Control. 2010; 3: 163–70.
    Search in Google Scholar
  26. 26. Duprez DA, Davis P, Botha J. The Ageless Study: The effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients =65 years of age with systolic hypertension. Circulation.2008; 118: 886–7.
    Open DOISearch in Google Scholar
  27. 27. Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003; 42: 1137–43.
    Open DOISearch in Google Scholar
  28. 28. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005; 111: 1012-8.
    Open DOISearch in Google Scholar
  29. 29. Schmieder RE, Philipp T, Guerediaga J et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009; 119: 417–25.
    Open DOISearch in Google Scholar
  30. 30. Lu H, Rateri DL, Feldman DL et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008; 118(3): 984-93.
    Open DOISearch in Google Scholar
  31. 31. Renke M, Lizakowski S, Tylicki L, et al. Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-Placebo controlled, randomized, cross-over study. Adv Med Sci. 2014; 59(2): 256-60.
    Open DOISearch in Google Scholar
  32. 32. Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008; 52(3): 563-72.
    Open DOISearch in Google Scholar
  33. 33. Yamamoto E, Kataoka K, Dong YF et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension. 2009; 54(3): 633-8.
    Open DOISearch in Google Scholar
  34. 34. Imanishi T, Tsujioka H, Ikejima H et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008; 52(3): 563-72.
    Open DOISearch in Google Scholar
  35. 35. Kamal S. Aliskiren Augments the Activities of Anti-Oxidant Enzymes in Liver Homogenates of DOCA Salt-Induced Hypertensive Rats. SciRes. 2014; 2: 92-9.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.1515/sjecr-2015-0025 | Journal eISSN: 2956-2090 (formerly 2335-075X, 2956-0454) | Journal ISSN: 2956-0454 (formerly 1820-8665)
Journal RSS Feed
Language: English
Page range: 193 - 199
Submitted on: May 14, 2015
Accepted on: May 15, 2015
Published on: Oct 14, 2015
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Keywords:
Aliskiren,
Isolated rat heart,
Langendorff technique,
Oxidative stress
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2015 Sasa Plecevic, Olga Pechanova, Andrej Barta, Aleksandra Vranic, Jovana Jeremic, Ljiljana Arsenijevic, Nevena Jeremic, Vladimir Jakovljevic, Maja Jevdjevic, Dejan Stanojevic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 16 (2015): Issue 3 (September 2015)
Previous article
Next article